![NanoBio First - Funding Program for World-Leading Innovative R&D on Science and Technology_[Development of Innovative Diagnostic and Therapeutic Systems Based on Nanobiotechnology]](../../common/img/head_title.gif)
Researcher data
Yasuhiro MATSUMURA
Co-Core Researcher
Development of a new formulation of anticancer agents incorporated micelle targeting refractory cancer
There are few effective regimens for intractable cancers such as pancreatic, stomach, lung, and other cancers. It is also know that such refractory cancers possess abundant cancer stroma. In this project, we will establish several new monoclonal antibodies against cancer related interstitial molecules and then make new formulation of polymeric micelles tagged with the antibodies especially for refractory, stroma-rich cancers.
| Affiliation | Division of Developmental Therapeutics, Research Center for Innovative Oncology, National Cancer Center Hospital East |
| Specialty | Oncology, Antibody Delivery, Drug Delivery System |
| URL | |
| TEL | 04-7134-6857 |
| FAX | 04-7134-6857 |
 |
|
| Address | 6-5-1 Kashiwanoha, Kashiwa, Chiba 277－0882 |